BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsGlobeNewsWire • 03/31/26
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize AssetsGlobeNewsWire • 03/02/26
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)GlobeNewsWire • 12/31/25
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent ProgressGlobeNewsWire • 11/13/25
BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue SarcomasGlobeNewsWire • 11/07/25
BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025GlobeNewsWire • 11/05/25
BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus SocietyGlobeNewsWire • 10/23/25
BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025GlobeNewsWire • 10/20/25
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025GlobeNewsWire • 10/03/25
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDAGlobeNewsWire • 09/08/25
BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent ProgressGlobeNewsWire • 08/07/25
BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025GlobeNewsWire • 08/04/25
BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia MeetingGlobeNewsWire • 07/17/25
BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers CongressGlobeNewsWire • 07/03/25
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimenGlobeNewsWire • 06/02/25
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent ProgressGlobeNewsWire • 05/06/25
BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025GlobeNewsWire • 04/29/25
BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 04/24/25